Locally Advanced Clinical Trials in Toronto, Ontario
20 recruitingToronto, Ontario, Canada
Showing 1–20 of 20 trials
Recruiting
Phase 1
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
Locally Advanced Pancreatic CarcinomaStage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8+1 more
National Cancer Institute (NCI)18 enrolled11 locationsNCT05411094
Recruiting
Phase 3
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Locally Advanced Cervical Cancer
AstraZeneca800 enrolled204 locationsNCT06079671
Recruiting
Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca895 enrolled283 locationsNCT04862663
Recruiting
Phase 1
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Locally Advanced Head and Neck Squamous Cell CarcinomaClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Stage III Hypopharyngeal Carcinoma AJCC v8+23 more
National Cancer Institute (NCI)46 enrolled18 locationsNCT05172245
Recruiting
Phase 1
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic Solid Tumors
Avistone Biotechnology Co., Ltd.63 enrolled15 locationsNCT06307795
Recruiting
Phase 2
A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment
Locally Advanced Pancreatic Adenocarcinoma
University Health Network, Toronto43 enrolled2 locationsNCT06453486
Recruiting
Phase 3
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerER Positive Breast Cancer+1 more
Olema Pharmaceuticals, Inc.1,000 enrolled85 locationsNCT07085767
Recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Esophageal CancerGastric CancerCervical Cancer+5 more
Genentech, Inc.450 enrolled41 locationsNCT05581004
Recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Metastatic Solid TumorsLocally Advanced Solid TumorsRecurrent Solid Tumors
Genentech, Inc.250 enrolled18 locationsNCT06031441
Recruiting
Phase 1Phase 2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Metastatic Solid TumorsLocally Advanced Solid Tumors
Turning Point Therapeutics, Inc.500 enrolled165 locationsNCT03093116
Recruiting
Phase 2
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Esophageal AdenocarcinomaGastroesophageal Junction AdenocarcinomaLocally Advanced Unresectable or Metastatic Gastric Adenocarcinoma
AbbVie180 enrolled49 locationsNCT06628310
Recruiting
Phase 3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Locally Advanced Head and Neck Squamous Cell Carcinoma
AstraZeneca1,145 enrolled305 locationsNCT06129864
Recruiting
Phase 1
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Metastatic Solid TumorLocally Advanced Solid Tumor
Nuvalent Inc.200 enrolled21 locationsNCT06521554
Recruiting
Phase 3
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Servier Bio-Innovation LLC136 enrolled114 locationsNCT06127407
Recruiting
Phase 1Phase 2
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Locally AdvancedUnresectableMetastatic Cancers+1 more
Recursion Pharmaceuticals Inc.85 enrolled6 locationsNCT06678659
Recruiting
Phase 1
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Solid TumorsMetastatic Hepatocellular CarcinomaAdvanced Solid Tumors+11 more
Tyra Biosciences, Inc100 enrolled16 locationsNCT06915753
Recruiting
Phase 1Phase 2
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Metastatic Solid TumorLocally Advanced Solid Tumor
Nuvalent Inc.840 enrolled74 locationsNCT05384626
Recruiting
Phase 1Phase 2
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Metastatic Solid TumorLocally Advanced Solid Tumor
Nuvalent Inc.359 enrolled63 locationsNCT05118789
Recruiting
Phase 1Phase 2
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
Triple Negative Locally Advanced Non-resectable Breast Cancer
Marengo Therapeutics, Inc.50 enrolled8 locationsNCT06827613
Recruiting
Not Applicable
Low-Dose Weekly vs High-Dose Cisplatin
Locally Advanced Head and Neck Squamous Cell Carcinoma
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's100 enrolled3 locationsNCT03649048